$316.31
+1.3%West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Last Annual Value
600.00K
3-Year CAGR
-57%
5-Year CAGR
-41%
10-Year CAGR
-26%
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
600.00K | -59.1% | -41.2% | -21.1% | ||
![]() Incyte Corporation NASDAQ:INCY | 2.43M | -1.6% | 4.9% | -24.2% | |
![]() Medpace Holdings, Inc. NASDAQ:MEDP | 0.00 | N/A | N/A | N/A | |
![]() Hologic, Inc. NASDAQ:HOLX | 42.70M | -27.3% | -14.5% | -12.1% | |
![]() Quest Diagnostics Incorporated NYSE:DGX | 264.00M | 17.4% | 11.7% | 6.3% | |
![]() STERIS plc NYSE:STE | 60.70M | -18.2% | 10.3% | 3.6% | |
![]() Zimmer Biomet Holdings, Inc. NYSE:ZBH | 292.80M | 13.3% | 7.0% | -1.9% | |
![]() Illumina, Inc. NASDAQ:ILMN | 101.00M | 9.5% | 10.6% | 11.8% | |
![]() Waters Corporation NYSE:WAT | 50.77M | -19.9% | 2.5% | 1.2% | |
![]() Labcorp Holdings Inc. NYSE:LH | 224.10M | 3.9% | 1.1% | 0.2% | |
![]() The Cooper Companies, Inc. NASDAQ:COO | 100.00M | -1.7% | 34.1% | 14.3% |
Continue your WST research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.